Is a clinical stage bio-pharmaceutical company, developing disruptive gene therapies for inflammatory and age related diseases across human and animal healthcare.
Medexplore Ventures has led the founding of the company in 2021, which has later executed an exclusive license agreement with the Icahn School of Medicine at Mount Sinai in New York, NY. The license agreement provides Gromit with access to a broad patent portfolio related to Sphingolipids metabolizing enzyme (SME) and its therapeutic application in senescence, inflammation and aging. This high value technology has been developed in the lab of Efrat Eliyahu, PhD, Assistant Professor of Genetics and Genomics Sciences at Icahn Mount Sinai, and is addressing acute and chronic inflammatory diseases and related conditions. The therapeutic protein is administered as gene therapy via using adeno-associated-virus mediated delivery.